Saturday, November 30, 2019

Suven's Alzheimer's molecule fails to meet primary end point in phase-2 trial

SUVN-502's clinical trial data assumed significance as no new Alzheimer's drug has been approved since Forest Labs' Namenda in 2003

from Moneycontrol https://ift.tt/37SvPmC

No comments:

Post a Comment

  Finding symbol of isotops by proton and neutron